Aprea Therapeutics, Inc. financial data

Symbol
APRE on Nasdaq
Industry
Pharmaceutical Preparations
Location
3805 Old Easton Road, Doylestown, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 863 % +32.7%
Debt-to-equity 15.1 % -45.9%
Return On Equity -54.1 % +17.4%
Return On Assets -45.5 % +13.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.49M shares +1.14%
Common Stock, Shares, Outstanding 5.48M shares +46.7%
Entity Public Float 10M USD 0%
Common Stock, Value, Issued 5.48K USD +46.7%
Weighted Average Number of Shares Outstanding, Basic 5.51M shares +52.3%
Weighted Average Number of Shares Outstanding, Diluted 5.51M shares +52.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 6.46M USD -23.4%
Operating Income (Loss) -14.3M USD +7.45%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -13M USD +9.3%
Earnings Per Share, Basic -2.35 USD/shares +40.5%
Earnings Per Share, Diluted -2.45 USD/shares +38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.8M USD +5.75%
Assets, Current 23.6M USD +4.69%
Property, Plant and Equipment, Net 81.5K USD -7.74%
Other Assets, Noncurrent 282K USD
Assets 24M USD +5.87%
Accounts Payable, Current 1.35M USD -19%
Employee-related Liabilities, Current 465K USD -54.3%
Liabilities, Current 3.36M USD -23.4%
Liabilities 3.95M USD -48.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10.6M USD -0.15%
Retained Earnings (Accumulated Deficit) -321M USD -4.21%
Stockholders' Equity Attributable to Parent 19.3M USD +13.9%
Liabilities and Equity 24M USD +5.87%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.94M USD -32.1%
Net Cash Provided by (Used in) Financing Activities 14.7M USD +186%
Net Cash Provided by (Used in) Investing Activities -7.98K USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 5.48M shares +46.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22.9M USD +5.74%
Deferred Tax Assets, Valuation Allowance 50.2M USD +1.46%
Deferred Tax Assets, Gross 50.2M USD +1.46%
Payments to Acquire Property, Plant, and Equipment 7.98K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -13M USD +9.11%
Property, Plant and Equipment, Gross 154K USD +11.2%
Deferred Tax Assets, Operating Loss Carryforwards 41.1M USD -1.74%
Preferred Stock, Shares Authorized 40M shares 0%
Additional Paid in Capital 351M USD +4.57%
Depreciation, Depletion and Amortization 6.16K USD +1402%
Share-based Payment Arrangement, Expense 149K USD +96.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%